Europe Ovarian Cancer Diagnostics and Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

The European ovarian cancer diagnostics and therapeutics market is projected to register a CAGR of 8.6% during the forecast period.

The COVID-19 pandemic affected healthcare systems in Europe and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risk. According to the article by NCBI published in November 2020, surgical mortality in cancer patients who develop peri-operative COVID-19 has been reported to be as high as 25% which led to the postponement and modification of surgical and chemotherapy protocols during the peak of the pandemic. However, with the relaxation of restrictions, post-pandemic circumstances are expected to contribute to the market growth. As per the NCBI article published in January 2021, about 27% of women with ovarian cancer diagnosis faced a considerable change in patient care and support after the pandemic. Such an increase in ovarian cancer patient care during the post-pandemic period is expected to contribute to the growth of the market. The COVID-19 pandemic slowed down the growth rate in early 2020. However, owing to the relaxation of lockdown restrictions and normalization, the studied market is regaining its growth pace.

The major factors that drive the European ovarian cancer diagnostics and therapeutics market are the increasing geriatric women population, the rise in ovarian cancer cases, and the increasing use of combination therapies for the treatment of ovarian cancer. The incidence of ovarian cancer is high among women between the ages of 55 and 64 years. According to the article by OCRA published in May 2021, two-thirds of those diagnosed with ovarian cancer are 55 years or older. The major symptoms of ovarian cancer include bloating, pelvic and abdominal pain, difficulty eating, and urinary symptoms. As per the article by NCBI published in February 2022, ovarian cancer is the fifth most common cancer in Europe for females. Moreover, as per GLOBOCAN estimates for 2020, Europe recorded 74,592 new ovarian cancer cases in 2020. With the rising burden of cancer, there is a rising need for effective treatment.

Additionally, product approvals in Europe are expected to contribute to market growth during the forecast period. For instance, in May 2022, INEX Innovative received CE-IVD certification for its OvaCis Rapid Test for detecting cancer in ovarian cysts. The ovarian cancer product was planned to be launched in the EU markets by the end of the year.

Thus, owing to these factors, the market is expected to witness significant growth during the forecast period. However, the lack of accurate diagnosis of ovarian cancer is expected to restrain the market growth during the forecast period.

Europe Ovarian Cancer Diagnostics & Therapeutics Market Trends

Immunotherapy is Expected to Hold Significant Share of the European Ovarian Cancer Diagnostics and Therapeutics Market During the Forecast Period

Immunotherapy is a type of therapy that uses drugs to suppress or stimulate the immune system to help the body fight infection and ovarian cancer. It relates to a type of biological therapy for ovarian cancer treatment that boosts the body’s natural defenses to fight cancer. It may work by stopping or slowing the growth of cancer cells. It will also strengthen the immune system and prevent cancer from spreading to other parts of the body. These therapies are made by the body or in a laboratory to improve or restore immune system function. The increasing product launches for the treatment of ovarian cancer and product development are expected to drive the growth of the market studied during the forecast period.

For instance, the increasing research studies in the region are contributing to the growth of the market segment. For instance, in October 2022, Mendus AB planned for the release of the presentation of the first clinical data from the ongoing ALISON Phase I trial that evaluates the safety and feasibility of its maintenance immunotherapy product candidate DCP-001 in ovarian cancer.

Similarly, in October 2021, Alkermes PLC headquartered in Ireland, initiated ARTISTRY-7, Phase 3, an open-label, randomized trial evaluating the anti-tumor activity and safety of intravenously administered nemvaleukin alfa, in combination with pembrolizumab, in patients with platinum-resistant ovarian cancer.

Hence, owing to the above-mentioned factors, along with the rising burden of ovarian cancer, the market for chemotherapy is expected to grow during the forecast period.

The United Kingdom is Expected to Dominate the European Ovarian Cancer Diagnostics and Therapeutics Market Over the Forecast Period

The United Kingdom is expected to show significant growth during the forecast due to a high number of ovarian cancer cases reported in the country. In addition, there are a large number of clinical trials conducted in the country. According to data published by GLOBOCAN 2020, the incidence of ovarian cancer in the United Kingdom in 2020 was 6,065 cases. Such a high incidence of ovarian cancer in the United States is expected to drive the growth of the studied market in the United Kingdom.

Additionally, the development of ovarian diagnostics in the United Kingdom is expected to contribute to the growth of the market. In May 2022, the Universities of Manchester, Birmingham, and Exeter conducted a study to determine if human epididymis protein 4 (HE4), found in the blood, could help identify ovarian cancer more accurately and save other women from unnecessary and often invasive procedures such as biopsies and physical examinations. Such developments are expected to contribute to the growth of the market during the forecast period in the United Kingdom.

Furthermore, the availability of ovarian cancer therapeutics in the United States is expected to boost the growth of the market. For instance, in January 2021, Zejula, marketed by Tesaro, was available in the United Kingdom as maintenance therapy for advanced ovarian cancer.

Thus, the above-mentioned factors are expected to drive the growth of the market during the forecast period in the United Kingdom.

Europe Ovarian Cancer Diagnostics & Therapeutics Market Competitor Analysis

The European ovarian cancer diagnostics and therapeutics market consists of several major players and is moderately fragmented. The key players in the market include AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffman-La Roche Ltd, GlaxoSmithKline PLC, Johnson and Johnson, Amneal Pharmaceuticals, Siemens Healthineers AG, among others.

Additional benefits of purchasing the report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.